International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 1, 2009, Pages 303-305

  Brüggemann, Roger J M ^a   Touw, Daan J ^b,c   Aarnoutse, Rob E ^a   Verweij, Paul E ^a   Burger, David M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Pharmacy of the Hospitals of the Hague   (Netherlands)

^c Association for Quality Assessment in Therapeutic Drug Monitoring and Clinical Toxicology (KKGT)   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; HYDROXYITRACONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANALYTIC METHOD; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HEALTH PROGRAM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NORMAL HUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; AZOLES; BIOLOGICAL ASSAY; FLUCONAZOLE; HUMANS; ITRACONAZOLE; PYRIMIDINES; TRIAZOLES;

EID: 59749101276     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00901-08     Document Type: Article

References (9)

1. Aarnoutse, R. E., C. P. Verweij-van Wissen, E. W. van Ewijk-Beneken Kolmer, E. W. Wuis, P. P. Koopmans, Y. A. Hekster, and D. M. Burger. 2002. International interlaboratory quality control program for measurement of antiretroviral drugs in plasma. Antimicrob. Agents Chemother. 46:884-886.
2. Anonymous. 2001. Guidance for industry. Bioanalytical method validation. Center for Drug Evaluation and Research and Center for Veterinary Medicine, Food and Drug Administration, U.S. Department of Health and Human Services, Washington, DC. http://www.fda.gov/cder/guidance/4252fnl.htm.
3. Dominguez-Gil, H. A., N. A. Sanchez, and M. J. Garcia Sanchez. 2006. Therapeutic drug monitoring of itraconazole and the relevance of pharmacokinetic interactions. Clin. Microbiol. Infect. 12(Suppl. 7):97-106.
4. Droste, J. A., R. E. Aarnoutse, P. P. Koopmans, Y. A. Hekster, and D. M. Burger. 2003. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J. Acquir. Immune Defic. Syndr. 32:287-291.
5. Holland, D. T., R. DiFrancesco, J. Stone, F. Hamzeh, J. D. Connor, and G. D. Morse. 2004. Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob. Agents Chemother. 48: 824-831.
6. Pascual, A., T. Calandra, S. Bolay, T. Buclin, J. Bille, and O. Marchetti. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211.
7. Smith, J., and D. Andes. 2008. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther. Drug Monit. 30:167-172.
8. Steele, B. W., E. Wang, G. E. Palomaki, G. G. Klee, R. J. Elin, S. J. Soldin, and D. L. Witte. 2001. An evaluation of analytic goals for assays of drugs: a College of American Pathologists Therapeutic Drug Monitoring Survey Study. Arch. Pathol. Lab. Med. 125:729-735.
9. Walsh, T. J., E. J. Anaissie, D. W. Denning, R. Herbrecht, D. P. Kontoyiannis, K. A. Marr, V. A. Morrison, B. H. Segal, W. J. Steinbach, D. A. Stevens, J. A. van Burik, J. R. Wingard, and T. F. Patterson. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.